Regulatory milestones

AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of gastrointestinal stromal tumors. AB Science was appealing a November CHMP negative opinion.